Hims & Hers Health faces investigation over allegedly misleading statements.
ByAinvest
Wednesday, Jul 9, 2025 9:39 am ET1min read
HIMS--
The investigation centers on Hims & Hers' handling of GLP-1 receptor agonists, particularly semaglutide. Novo Nordisk, the manufacturer of semaglutide, terminated its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. The FDA has warned against unapproved ingredients and counterfeit products in compounded GLP-1s, emphasizing patient safety risks [3].
In response to the termination, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025 [1]. The FDA has resolved the Wegovy shortage by concluding that Novo Nordisk is fully meeting current and projected nationwide demand for the medicine [2]. To transition patients from knock-off compounded versions to authentic, FDA-approved Wegovy, Novo Nordisk has initiated a collaboration with telehealth companies, including Hims & Hers. However, Hims & Hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the guise of 'personalization' and has been disseminating deceptive marketing that puts patient safety at risk [1].
If you are a shareholder who suffered a loss, the DJS Law Group encourages you to contact them to discuss your rights [1].
References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--hims-302500946.html
[2] https://www.morningstar.com/news/pr-newswire/20250709la26723/hims-hers-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-hims
[3] https://www.pharmacytimes.com/view/novo-nordisk-drops-hims-hers-inside-the-compounded-glp-1-crisis
MORN--
NVO--
OGN--
• Hims & Hers Health under investigation for securities violations • Allegations of misleading statements and undisclosed information • Novo Nordisk terminates collaboration due to illegal mass compounding and deceptive marketing • FDA resolved Wegovy shortage based on meeting nationwide demand • Transitioning patients to authentic Wegovy through NovoCare Pharmacy
Hims & Hers Health, Inc. (NYSE: HIMS), a telehealth company specializing in men's and women's health, is under investigation for potential securities violations. The DJS Law Group has announced it is investigating claims on behalf of Hims & Hers investors, alleging the company issued misleading statements and failed to disclose pertinent information [1].The investigation centers on Hims & Hers' handling of GLP-1 receptor agonists, particularly semaglutide. Novo Nordisk, the manufacturer of semaglutide, terminated its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. The FDA has warned against unapproved ingredients and counterfeit products in compounded GLP-1s, emphasizing patient safety risks [3].
In response to the termination, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025 [1]. The FDA has resolved the Wegovy shortage by concluding that Novo Nordisk is fully meeting current and projected nationwide demand for the medicine [2]. To transition patients from knock-off compounded versions to authentic, FDA-approved Wegovy, Novo Nordisk has initiated a collaboration with telehealth companies, including Hims & Hers. However, Hims & Hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the guise of 'personalization' and has been disseminating deceptive marketing that puts patient safety at risk [1].
If you are a shareholder who suffered a loss, the DJS Law Group encourages you to contact them to discuss your rights [1].
References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--hims-302500946.html
[2] https://www.morningstar.com/news/pr-newswire/20250709la26723/hims-hers-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-hims
[3] https://www.pharmacytimes.com/view/novo-nordisk-drops-hims-hers-inside-the-compounded-glp-1-crisis
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet